CHAPEL HILL, NC – Oncology research firm Heat Biologics is set to go public two weeks from today and has upped the maximum offering price to more than $33.1 million, according to a securities filing.
In a previous filing, that total was listed as $24 million.
Heat, whose public filing was revealed in May, would join a host of other local life science companies newly represented on Wall Street, such as Quintiles (NYSE: Q), Liposcience (Nasdaq: LPDX) and Chimerix (Nasdaq: CMRX).
As previously reported, the company hopes to sell between $10 and $12 per shareunder the symbol “HTBX.”
The sole book-running manager is Aegis Capital Corp., and Cantor Fitzgerald & Co is serving as co-manager.
Heat watchers may want to review an interview we had earlier this year with Heat CEO Jeff Wolf on the science behind his oncology platform.